

2019 Information

Date of announcement	Date of announcement	Statement
2019/1/14	16:09:30	<p>To disclose the business agreement with Energenesis Biomedical Co., Ltd.</p> <p>1.Date of occurrence of the event:2019/01/14</p> <p>2.Counterparty to the contract or commitment: Energenesis Biomedical Co., Ltd.</p> <p>3.Relationship to the Company: NA</p> <p>4.Starting and ending dates (or rescission date) of the contract or commitment: 2019/01/14~2024/01/14</p> <p>5.Major content (not applicable where rescinded): Commissioned to manufacture API.</p> <p>6.Restrictive covenants (not applicable where rescinded): Confidential disclosure clause.</p> <p>7.Effect on company finances and business (not applicable where rescinded): In the short run, there will be revenues coming from the manufacturing. In the future, the project could enhance the expertises related to clinical trials with new drug developers.</p> <p>8.Concrete purpose/objective (not applicable where rescinded): To obtain the know-how on integration in pharmaceuticals industry.</p> <p>9.Any other matters that need to be specified: NA</p>
2019/1/17	14:09:31	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2019/01/18</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference: 20F., No.2, Sec. 1, Chongqing S. Rd.,Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>
2019/1/21	12:24:55	<p>Clarification on media reporting.</p> <p>1.Date of occurrence of the event:2019/01/21</p> <p>2.Company name:SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4.Reciprocal shareholding ratios:Not applicable</p> <p>5.Name of the reporting media:1/21/2019 Economic Daily News A14 Layout</p> <p>6.Content of the report:</p>

		<p>(1)2018 after tax profit was some 450 million and after tax EPS expects to reach 5.6/share, both reaching historical highs.</p> <p>(2) Dividend payout ratio might be lower than last year's, but the dividend is expected to hike.</p> <p>7.Cause of occurrence:</p> <p>(1)The report is simply a forecast made by outsiders. SCI hasn't disclosed to the public 2018 financial forecast and, therefore, all information should be based on and referred to what has been disclosed on the Market Observation Post System.</p> <p>(2) Dividend distribution will be disclosed right after the board meeting to be held in March.</p> <p>8.Countermeasures: Issued the critical notice to make a clarification.</p> <p>9.Any other matters that need to be specified:</p> <p>Unaudited 2018 Jan.-Nov. pretax income of SCI was NT\$505,730 thousand. For details, please refer to M.O.P.S..</p>
2019/3/7	16:34:27	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2019/03/08</p> <p>2.Time of the investor conference:15:10</p> <p>3.Location of the investor conference:3F., No.2, Songshou Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference:</p> <p>Brief recent operating results</p> <p>5.The presentation of the investor conference release:</p> <p>http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website:</p> <p>http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>
2019/3/13	17:04:04	<p>Appointment of Company Secretary</p> <p>1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.) financial officer, accounting officer, Company Secretary, research and development officer, or internal audit officer): Company Secretary</p> <p>2.Date of occurrence of the change:2019/03/13</p> <p>3.Name, title, and resume of the replaced person: NA</p> <p>4.Name, title, and resume of the replacement: Deiter Yang, Financial Manager</p> <p>5.Type of the change (please enter: "resignation", "position adjustment", "dismissal", "retirement", "death" or "new replacement"):New replacement</p> <p>6.Reason for the change: New replacement</p> <p>7.Effective date:2019/03/13</p> <p>8.Any other matters that need to be specified: NA</p>

2019/3/13	17:04:25	<p>Convention of 2019 general shareholders' meeting.</p> <ol style="list-style-type: none"> 1.Date of the board of directors resolution:2019/03/13 2.Date for convening the shareholders' meeting:2019/06/21 3.Location for convening the shareholders' meeting: No.55, Changrong Rd., Luzhu Dist., Taoyuan City, Taiwan (Freedom design hotel) 4.Cause or subjects for convening the meeting <ol style="list-style-type: none"> (1)Report Items: <ol style="list-style-type: none"> (1)Report on the compensation for employees and directors of 2018 (2)Report on operating results of 2018 (3)Report by Audit Committee on auditing of 2018 financial statements (4)Report on donation to related parties 5.Cause or subjects for convening the meeting <ol style="list-style-type: none"> (2)Matters for Ratification: <ol style="list-style-type: none"> (1)Recognition of 2018 operation report and financial statements (2)Distribution of retained earnings 6.Cause or subjects for convening the meeting <ol style="list-style-type: none"> (3)Matters for Discussion: <ol style="list-style-type: none"> (1)Amendment to Procedure for Acquisition and Disposal of Assets. (2)Amendment to Subsidiary's Procedure for Acquisition and Disposal of Assets. (3)Amendment to Procedure governing the election of directors. (4)Lifting ban on directors from running the same business as SCI. 7.Cause or subjects for convening the meeting <ol style="list-style-type: none"> (4)Elections: Election of directors 8.Cause or subjects for convening the meeting <ol style="list-style-type: none"> (5)Other Proposals: N/A 9.Cause or subjects for convening the meeting <ol style="list-style-type: none"> (6)Extemporaneous Motions: N/A 10.Book closure starting date:2019/04/23 11.Book closure ending date:2019/06/21 12.Any other matters that need to be specified: N/A
2019/3/13	17:04:43	<p>Donation to related party.</p> <ol style="list-style-type: none"> 1.Date of occurrence of the event:2019/03/13 2.The reason for the donation: Support Criminal study 3.The total amount of the donation:NTD300,000 4.Counterparty to the donation: Criminal Investigation Foundation of R.O.C. 5.Relationship to the Company: Related Party 6.Name and resume of the independent director that expressed objection or reservation: NA 7.Contents of the objection or reservation: NA

		8.Any other matters that need to be specified: NA
2019/3/13	17:05:01	<p>Board of Directors approved the compensation for employees and directors of 2018</p> <p>1.Date of occurrence of the event:2019/03/13</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4.Reciprocal shareholding ratios: NA</p> <p>5.Cause of occurrence: NA</p> <p>6.Countermeasures:NA</p> <p>7.Any other matters that need to be specified:</p> <p>(1)Employees' compensation was NT\$53,166,686</p> <p>(2)Directors' compensation was NT\$7,204,548</p> <p>(3)The above compensations will be distributed in cash.</p> <p>(4)The total amount approved is not different from the expense recognized in 2018 financial statements.</p>
2019/3/13	17:05:18	<p>To announce board meeting's resolution on investment structure change.</p> <p>1.Date of occurrence of the event:2019/03/13</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4.Reciprocal shareholding ratios: NA</p> <p>5.Cause of occurrence:</p> <p>In view of no more essential operational needs, the board approved the dissolution of Yushan Holding Universal Ltd., a 100 percent-owned subsidiary registered on Cayman Islands.</p> <p>6.Countermeasures:</p> <p>The shareholding in Yushan Pharmaceuticals, Inc. 100 percent-owned by Yushan Holding Universal Ltd. will be transferred to the ownership of SCI Pharmtech Inc. in book value.</p> <p>7.Any other matters that need to be specified: NA</p>
2019/3/13	17:05:35	<p>To announce company dissolution on behalf of Yushan Holding Universal Ltd., an substantial subsidiary.</p> <p>1.Date of the board of directors resolution:2019/03/13</p> <p>2.Reason for dissolution: No more essential operational needs.</p> <p>3.Anticipated date of shareholders' meeting: NA</p> <p>4.Any other matters that need to be specified: NA</p>

2019/3/13	17:05:52	<p>To announce the capital reduction on behalf of Yushan Pharmaceuticals, Inc., an substantial subsidiary.</p> <ol style="list-style-type: none"> 1.Date of the board of directors resolution:2019/03/13 2.Reason for the capital reduction: To cover accumulated deficit 3.Amount of the capital reduction:NT\$19,239,090 4.Cancelled shares:1,923,909 shares 5.Capital reduction ratio:5.1857% 6.Share capital after the capital reduction:NT\$351,760,910 7.Scheduled date of the shareholders' meeting: NA 8.Estimate listed common shares after the capital reduction: NA 9.The estimate ratio of listed shares to the company's issued common shares, after the capital reduction: NA 10.Countermeasures of the lower circulation in shareholding, if the aforesaid estimate listed common shares does not reach 60 million shares and the ration does not reach 25% after the capital reduction: NA 11.Any other matters that need to be specified: NA
2019/3/13	17:06:09	<p>The Board proposed earnings distribution.</p> <ol style="list-style-type: none"> 1.Date of the board of directors resolution :2019/03/13 2.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):4.2 3.Cash distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0 4.Total amount of cash distributed to shareholders (NT\$):333,838,302 5.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):0 6.Stock distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0 7.Total amount of stock distributed to shareholders (shares):0 8.Any other matters that need to be specified: NA
2019/3/18	15:40:36	<p>Invited to brief recent operating results</p> <ol style="list-style-type: none"> 1.Date of the investor conference:2019/03/19 2.Time of the investor conference:14:30 3.Location of the investor conference: 13F., No.255, Sec. 3, Nanjing E. Rd., Taipei City 4.Brief information disclosed in the investor conference: Brief recent operating results 5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/ 6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw

		7.Any other matters that need to be specified: NA
2019/3/20	09:32:08	<p>Clarification on media reporting.</p> <p>1.Date of occurrence of the event:2019/03/20</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4.Reciprocal shareholding ratios: Not applicable</p> <p>5.Name of the reporting media: 03/20/2019 Economic Daily News C6 Layout</p> <p>6.Content of the report:</p> <p>(1)The company's sales in the first quarter will reach 560 million with an estimated 1.9/share EPS.</p> <p>(2)The 2019 sales is going to reach 2.213 billion with EPS expected to top 6.9/share. is expected to hike.</p> <p>7.Cause of occurrence: The report is simply a forecast made by outsiders. SCI hasn't disclosed to the public 2019 financial forecast and, therefore, all information should be based on and referred to what has been disclosed on the Market Observation Post System.</p> <p>8.Countermeasures: Issued the critical notice to make a clarification.</p> <p>9.Any other matters that need to be specified: January unaudited operating results have already been disclosed on the said website. The pretax income was 66 million. As for February's, they are not disclosed yet.</p>
2019/3/20	10:23:50	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2019/03/21</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:2F., No.99, Fuxing N. Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>

2019/5/17	14:29:24	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2019/05/20</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:7F., No. 236, Sec. 4, Sinyi Rd.,Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company’s website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>
2019/6/21	15:37:40	<p>Notice of re-election of functional committees'</p> <p>Members</p> <p>1.Date of occurrence of the change:2019/06/21</p> <p>2.Name of the functional committees: Audit Committee & Remuneration Committee.</p> <p>3.Name and resume of the replaced member:</p> <p>Audit Committee</p> <p>Mr. Ted Tu, Chairman of Hsuan Ho technology Ltd.</p> <p>Mr. Hung-Chih Wu, General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>Mr. Chia-Chun Jay Chen, Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>Remuneration Committee</p> <p>Mr. Ted Tu, Chairman of Hsuan Ho technology Ltd.</p> <p>Mr. Hung-Chih Wu, General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>Mr. Chia-Chun Jay Chen, Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>4.Name and resume of the new member:</p> <p>Audit Committee</p> <p>Mr. Ted Tu, Chairman of Hsuan Ho technology Ltd.</p> <p>Mr. Hung-Chih Wu, General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>Mr. Chia-Chun Jay Chen, Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>Remuneration Committee</p> <p>Mr. Ted Tu, Chairman of Hsuan Ho technology Ltd.</p> <p>Mr. Hung-Chih Wu, General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>Mr. Chia-Chun Jay Chen, Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>5.Type of the change (please enter: “resignation”, “discharge”, “tenure expired”, “death” or “new appointment”):tenure expired</p>

		<p>6.Reason of the change: re-election due to tenure expiration</p> <p>7.Original term (from _____ to _____): _____):2016/06/21~2019/06/20</p> <p>8.Effective date of the new member:2019/06/21</p> <p>9.Any other matters that need to be specified: NA</p>
2019/6/21	15:38:05	<p>1.Date of the shareholders' meeting resolution:2019/06/21</p> <p>2.Name and title of the director with permission to engage in competitive conduct: Director: Mr. Hung-Chih Wu General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>3.Items of competitive conduct in which the director is permitted to engage: Companies running the same or similar businesses with SCI.</p> <p>4.Period of permission to engage in the competitive conduct: During the term of the Director.</p> <p>5.Circumstances of the resolution (please describe the results of the voting under Article 209 of the Company Act): Approved by more than two thirds of the voting rights exercised by the shareholders representing a majority of the outstanding shares.</p> <p>6.If the permitted competitive conduct is business of a mainland China area enterprise, the name and title of the director (if it is not business of a mainland China area enterprise, please enter "not applicable" below): NA</p> <p>7.Company name of the mainland China area enterprise and the director's position in the enterprise: NA</p> <p>8.Address of the mainland China area enterprise: NA</p> <p>9.Business items of the mainland China area enterprise: NA</p> <p>10.Degree of effect on the Company's finances and business: NA</p> <p>11.If the director has invested in the mainland China area enterprise, the monetary amount of the director's investment and the director's shareholding ratio: NA</p> <p>12.Any other matters that need to be specified: NA</p>
2019/6/21	15:38:25	<p>Notice of the resolutions of 2019 general shareholders' meeting.</p> <p>1.Date of the shareholders' meeting:2019/06/21</p> <p>2.Important resolutions (1)profit distribution/deficit compensation: Approved the distribution of retained earnings. 43,254,232 shares represented by shareholders present in person or by proxy. (including 14,438,626 shares casted electronically) approval votes : 35,136,197 votes - 81.23% of the total represented at the time of voting. disapproval votes : 12,817 votes - 0.02% of the total represented at the time of voting. invalid votes: 0 votes - 0% of the total represented at the time of voting.</p>

abstention votes/no votes : 8,105,218 votes - 18.73% of the total represented at the time of voting.

3.Important resolutions (2)amendments of the corporate charter: NA

4.Important resolutions (3)business report and financial statements:
 Approved the operation report and financial statement of 2018.
 43,254,232 shares represented by shareholders present in person or by proxy.
 (including 14,438,626 shares casted electronically)
 approval votes : 35,120,189 votes - 81.19% of the total represented at the time of voting.
 disapproval votes : 12,815 votes - 0.02% of the total represented at the time of voting.
 invalid votes: 0 votes - 0% of the total represented at the time of voting.
 abstention votes/no votes : 8,121,228 votes - 18.77% of the total represented at the time of voting.

5.Important resolutions (4)elections of board of directors and supervisors:
 Re-election of directors.
 Elected as below:
 Directors:
 (1)Mercuries & Associates, Holding Ltd.
 Representative: Mr. Weichyun Wong; 37,650,115 votes
 (2)Mercuries & Associates, Holding Ltd.
 Representative: Mr. Henry Chen; 36,239,110 votes
 (3)Mercuries & Associates, Holding Ltd.
 Representative: Ms. Aurora Chen; 35,239,077 votes
 (4)Mercuries & Associates, Holding Ltd.
 Representative: Mr. Wen-Chih Chou; 34,543,092 votes
 Independent directors:
 Mr. Ted Tu; 30,775,119 votes
 Mr. Hung-Chih Wu; 30,558,298 votes
 Mr. Chia-Chun Jay Chen; 30,418,456 votes

6.Important resolutions (5)other proposals:
 (1)Approved the amendments to Procedure for Acquisition and Disposal of Assets.
 43,314,553 shares represented by shareholders present in person or by proxy.
 (including 14,438,626 shares casted electronically)
 approval votes : 35,067,936 votes - 80.96% of the total represented at the time of voting.
 disapproval votes : 12,889 votes - 0.02% of the total represented at the time of voting.
 invalid votes: 0 votes - 0% of the total represented at the time of voting.
 abstention votes/no votes : 8,233,728 votes - 19% of the total represented at the time of voting.

(2)Approved the amendment to Subsidiary's Procedure for Acquisition and

		<p>Disposal of Assets.</p> <p>43,314,553 shares represented by shareholders present in person or by proxy. (including 14,438,626 shares casted electronically)</p> <p>approval votes : 35,067,934 votes - 80.96% of the total represented at the time of voting.</p> <p>disapproval votes : 12,887 votes - 0.02% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 8,233,732 votes - 19% of the total represented at the time of voting.</p> <p>(3)Approved the amendment to Procedure governing the election of directors. 43,314,553 shares represented by shareholders present in person or by proxy. (including 14,438,626 shares casted electronically)</p> <p>approval votes : 35,065,938 votes - 80.95% of the total represented at the time of voting.</p> <p>disapproval votes : 14,886 votes - 0.03% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 8,233,729 votes - 19% of the total represented at the time of voting.</p> <p>(4)Approved the lifting of ban on director from running the same business as SCI. 43,314,553 shares represented by shareholders present in person or by proxy. (including 14,438,626 shares casted electronically)</p> <p>approval votes : 34,061,540 votes - 78.63% of the total represented at the time of voting.</p> <p>disapproval votes : 323,298 votes - 0.74% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 8,929,715 votes - 20.61% of the total represented at the time of voting.</p> <p>7.Any other matters that need to be specified: NA</p>
2019/6/21	15:45:17	<p>List of the Company's elected directors.</p> <p>1.Date of occurrence of the change:2019/06/21</p> <p>2.Appointment of or changed personnel (juristic-person director, juristic-person supervisor, independent director, natural-person director or natural-person supervisor):juristic-person director, independent director</p> <p>3.Title, name and resume of the replaced personnel:</p> <p>(1)Director: Mercuries & Associates, Holding Ltd.</p> <p>Representative : Mr. Weichyun Wong</p> <p>General manager of SCI Pharmtech, Inc.</p>

	<p>(2)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Henry Chen Chairman of Mercuries & Associates, Ltd.</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen Manager of Mckinsey & Company</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou R&D manager of SCI Pharmtech, Inc.</p> <p>(5)Independent director: Mr. Ted Tu Chairman of Hsuan Ho technology Ltd.</p> <p>(6)Independent director: Mr. Hung-Chih Wu General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>(7)Independent director: Mr. Chia-Chun Jay Chen Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>4.Title, name and resume of the new personnel:</p> <p>(1)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Weichyun Wong General manager of SCI Pharmtech, Inc.</p> <p>(2)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Henry Chen Chairman of Mercuries & Associates, Ltd.</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen Director of Shanghai American School</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou Factory manager of SCI Pharmtech, Inc.</p> <p>(5)Independent director: Mr. Ted Tu Chairman of Hsuan Ho technology Ltd.</p> <p>(6)Independent director: Mr. Hung-Chih Wu General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>(7)Independent director: Mr. Chia-Chun Jay Chen Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>5.Type of the change (please enter: “resignation”, “discharge”, “tenure expired”, “death” or “new appointment”):tenure expired</p> <p>6.Reason for the change:re-election due to tenure expiration</p> <p>7.Number of shares held by the new personnel at the time of appointment:</p> <p>(1)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Weichyun Wong; 25,236,132 shares</p>
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		<p>(2)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Henry Chen; 25,236,132 shares</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen; 25,236,132 shares</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou; 25,236,132 shares</p> <p>(5)Independent director: Mr. Ted Tu; 0 share</p> <p>(6)Independent director: Mr. Hung-Chih Wu; 0 share</p> <p>(7)Independent director: Mr. Chia-Chun Jay Chen; 0 share</p> <p>8.Original term (from _____ to _____):2016/06/21~2019/06/20</p> <p>9.Effective date of the new appointment:2019/06/21</p> <p>10.Rate of turnover of directors of the same term: NA</p> <p>11.Rate of turnover of supervisor of the same term:NA</p> <p>12.Rate of turnover of independent director of the same term:NA</p> <p>13.Change in one-third or more of directors (“Yes” or “No”):No</p> <p>14.Any other matters that need to be specified:NA</p>
2019/6/27	10:57:47	<p>Clarification on media reporting.</p> <p>1.Date of occurrence of the event:2019/06/27</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office</p> <p>4.Reciprocal shareholding ratios: Not applicable</p> <p>5.Name of the reporting media:6/27/2019 Commercial Times B5 Layout</p> <p>6.Content of the report: 2019 EPS expects to reach 7/share, reaching historical high.</p> <p>7.Cause of occurrence: The report is simply a forecast made by outsiders. SCI hasn’t disclosed to the public 2019 financial forecast and, therefore, all information should be based on and referred to what has been disclosed on the Market Observation Post System.</p> <p>8.Countermeasures: Issued the critical notice to make a clarification.</p> <p>9.Any other matters that need to be specified: Unaudited 2019 Jan.-May pretax income of SCI was NT\$355,465 thousand. For details, please refer to M.O.P.S..</p>
2019/6/27	14:57:29	<p>Invited to brief recent operating results.</p> <p>1.Date of the investor conference:2019/06/28</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:13F., No.8, DongXing Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p>

		<p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company’s website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>
2019/7/5	14:56:37	<p>Notice of the re-election of chairman of the Board of Directors.</p> <p>1.Date of the board of directors resolution or date of occurrence of the change:2019/07/05</p> <p>2.Type of personnel (chairman or general manager):chairman</p> <p>3.Name and resume of the replaced personnel: Mr. Weichyun Wong, Chairman of SCI Pharmtech, Inc.</p> <p>4.Name and resume of the new personnel: Mr. Weichyun Wong, Chairman of SCI Pharmtech, Inc.</p> <p>5.Type of the change (please enter: “resignation”, “conge”, “tenure expired”, “position adjustment”, “dismissal”, “retirement”, “death” or “new appointment”):tenure expired</p> <p>6.Reason for the change: re-election due to tenure expiration</p> <p>7.Effective date of the new appointment:2019/07/05</p> <p>8.Any other matters that need to be specified: NA</p>
2019/7/5	14:57:03	<p>Notice of the record date for common share dividend.</p> <p>1.Date of the resolution by the board of directors or shareholders' meeting or decision by the Company: 2019/07/05</p> <p>2.Type of ex-rights or ex-dividend (please enter: “Ex-rights”, ”Ex-dividend”, or ”Ex-rights and dividend”):Ex-dividend</p> <p>3.Type and monetary amount of dividend distribution: Cash dividends of NT\$333,838,302</p> <p>4.Ex-rights (ex-dividend) trading date:2019/07/23</p> <p>5.Last date before book closure:2019/07/24</p> <p>6.Book closure starting date:2019/07/25</p> <p>7.Book closure ending date:2019/07/29</p> <p>8.Ex-rights (ex-dividend) record date:2019/07/29</p> <p>9.Any other matters that need to be specified: The payment date of the cash distribution is August 16, 2019.</p>
2019/9/11	14:58:38	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2019/09/12</p> <p>2.Time of the investor conference:14:00</p> <p>3.Location of the investor conference: 3F., No.2, Songshou Rd., Taipei City</p>

		<p>4. Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5. The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6. Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p> <p>7. Any other matters that need to be specified: NA</p>
2019/10/25	17:11:22	<p>Declare that the Company is going to acquire privately placed securities.</p> <p>1. Name and nature of the subject matter (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g. dividend yield): Privately placed securities of Energenesis Biomedical Co., Ltd.</p> <p>2. Date of occurrence of the event: 2019/10/25</p> <p>3. Volume, unit price, and total monetary amount of the transaction: Volume : 322,000 shares Unit price: NTD62.10 / per share Total amount: NTD19,996,200</p> <p>4. Counterpart to the trade and its relationship to the Company (if the trading counterpart is a natural person and furthermore is not an actual related party of the Company, the name of the trading counterpart is not required to be disclosed): Energenesis Biomedical Co., Ltd.</p> <p>5. Where the counterpart to the trade is an actual related party, a public announcement shall also be made of the reason for choosing the related party as trading counterpart and the identity of the previous owner (including its relationship with the company and the trading counterpart), price of transfer, and date of acquisition: None</p> <p>6. Where a person who owned the property within the past five years has been an actual related person of the company, a public announcement shall also include the dates and prices of acquisition and disposal by the related person and the person's relationship to the company at those times: None</p> <p>7. Matters related to the creditor's rights currently being disposed of (including types of collateral of the disposed creditor's rights; if the creditor's rights are creditor's rights toward a related person, the name of the related person and the book amount of the creditor's rights toward such related person currently being disposed of must also be announced): None</p> <p>8. Anticipated profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status or recognition shall be stated and explained): None</p> <p>9. Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important stipulations: Payment term: 2019/10/16-2019/10/30</p>

		<p>10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making department: The transaction was decided by both audit committee meeting and board meeting and the price was based on 80% average closing price of the 30 days right before Oct. 16.</p> <p>11.Net worth per share of company underlying securities acquired or disposed of: NTD12.37</p> <p>12.The discrepancy between the reference price of private placement and the transaction amount per share is 20 percent or more of the transaction amount:None</p> <p>13.Current cumulative volume, amount, and shareholding percentage of holdings of the security being traded (including the current trade) and status of any restriction of rights (e.g.pledges): Cumulative volume : 1,458,000 shares Cumulative amount : NTD64,981,700. Shareholding percentage of holdings of the security being traded (including the current trade) : 2.49% Any restriction of rights: None</p> <p>14.Current ratio of private placement of securities (including the current trade) to the total assets and shareholder's equity as shown in the most recent financial statement and the operating capital as shown in the most recent financial statement: To total assets: 1.32% To shareholder's equity: 1.57% To operating capital: 4.48%</p> <p>15.Broker and broker's fee:None</p> <p>16.Concrete purpose or use of the acquisition or disposition: To stabilize the foundation of business cooperation and form strategic alliance.</p> <p>17.Do the directors have any objection to the present transaction?:No</p> <p>18.The trading counterparty is a related party:No</p> <p>19.Approval date by board of directors:2019/10/25</p> <p>20.Recognition date by supervisors or submission date by audit committee: 2019/10/25</p> <p>21.Has the CPA issued an opinion on the unreasonableness of the price of the current transaction: None</p> <p>22.Name of the CPA firm: None</p> <p>23.Name of the certifying CPA: None</p> <p>24.The practice certificate number of the CPA: None</p> <p>25.Any other matters that need to be specified: None</p>
--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2019/12/3	08:14:12	<p>1.Date of the investor conference:2019/12/05</p> <p>2.Time of the investor conference:15:00</p> <p>3.Location of the investor conference: No. 85, Sec. 4, Roosevelt Rd., Taipei City (GIS NTU Convention Center)</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>
2019/12/13	17:27:12	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2019/12/13</p> <p>2.The reason for the donation: Promote domestic sports culture</p> <p>3.The total amount of the donation: NT\$4,500,000</p> <p>4.Counterparty to the donation: Foundation for Taiwan Masters Golf Tournament</p> <p>5.Relationship to the Company: Related Party</p> <p>6.Name and resume of the independent director that expressed objection or reservation: NA</p> <p>7.Contents of the objection or reservation: NA</p> <p>8.Any other matters that need to be specified: NA</p>